Su Zhen has filed 2 SEC Form 4 filings across 2 companies in the last 90 days.
Profile
Su Zhen is listed in SEC filings as associated with Karyopharm Therapeutics Inc. as of May 26, 2026. Based on the SEC context provided, Su Zhen appears to be a board member or director of Karyopharm Therapeutics Inc. at that time. Publicly accessible information beyond this SEC filing is limited, so the available biography is confined to this context. Karyopharm Therapeutics is a Nasdaq-listed oncology company known for therapies targeting nuclear export, including XPOVIO (selinexor).
Role
Insider
Notability
40/100
Board memberships
Karyopharm Therapeutics Inc.
Awards & honors
Appointed as director of Karyopharm Therapeutics Inc. (per SEC filing, 2026-05-26)
Su Zhen is listed in SEC filings as associated with Karyopharm Therapeutics Inc. as of May 26, 2026. Based on the SEC context provided, Su Zhen appears to be a board member or director of Karyopharm Therapeutics Inc. at that time. Publicly accessible information beyond this SEC filing is limited, so the available biography is confined to this context. Karyopharm Therapeutics is…
How many SEC Form 4 filings has Su Zhen submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Where can I see all of Su Zhen's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
